News | August 13, 2024
Supriya Lifescience reports robust Q1 FY25 results with 21.7% revenue growth
European markets now contribute 51% of our business revenue up from 43% in Q4 FY24 and 34% in Q1 FY24
European markets now contribute 51% of our business revenue up from 43% in Q4 FY24 and 34% in Q1 FY24
The results are an outcome of the company's focus on sustainable and profitable growth and reflects all the hard work and focus teams have put in over the years
The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore
International Business is expected to register double-digit growth in constant currency terms
General Medicine grows 5% and Vaccines 10% led by Shingrix
Low-leveraged balance sheets, sizeable liquidity to keep credit profiles stable
Operating EBITDA increased by 21% to INR 181 crores in Q4 FY23
Profit After Tax (PAT) for the quarter ended December 31, 2022 was at Rs. 290.8 crore as compared to Rs. 239.8 crore in the previous corresponding quarter, registering a growth of 21.3% YoY
Profit after Tax stood at Rs. 106 crore as compared to Rs. 84 crore registering growth of 26%
International Business is expected to post double-digit revenue growth during the quarter in constant currency.
Subscribe To Our Newsletter & Stay Updated
